Sonoma Pharmaceuticals' (SNOA) CEO James Schutz on Q2 2019 Results - Earnings Call Transcript

Our Alevicyn product already on the market has made a small and interesting dent into the prescription itch market as an alternative to topical steroids. On Slide 5, you’ll see a photograph of our …